{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:42Z","timestamp":1791204642822,"version":"4.2.0"},"reference-count":49,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACS Omega"],"published-print":{"date-parts":[[2024,2,27]]},"DOI":"10.1021\/acsomega.3c05170","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:36:45Z","timestamp":1708043805000},"page":"8773-8788","source":"Crossref","is-referenced-by-count":23,"title":["Synthesis and Trace-Level Quantification of Mutagenic and Cohort-of-Concern Ciprofloxacin Nitroso Drug Substance-Related Impurities (NDSRIs) and Other Nitroso Impurities Using UPLC-ESI-MS\/MS\u2500Method Optimization Using I-Optimal Mixture Design"],"prefix":"10.1021","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-9014","authenticated-orcid":true,"given":"Srinivas","family":"Nakka","sequence":"first","affiliation":[{"name":"Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad 502329, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh Kumar","family":"Katari","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad 502329, India"},{"name":"School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva Krishna","family":"Muchakayala","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad 502329, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6501-8875","authenticated-orcid":true,"given":"Sreekantha Babu","family":"Jonnalagadda","sequence":"additional","affiliation":[{"name":"School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-1242","authenticated-orcid":true,"given":"Surendra Babu","family":"Manabolu Surya","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad 502329, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"ref1\/cit1","unstructured":"2023 https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/ciprofloxacin#section=NCI-Thesaurus-Code (accessed May 25)."},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202212_30489"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220317162132"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.1c00077"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1025633"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121388"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00071312"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.15267"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122533"},{"key":"ref11\/cit11","unstructured":"Control of impurities of pharmacopoeial\nsubstances - Scientific guideline\n| European Medicines Agency (europa.eu) International Conference on\nHarmonisation of Technical Requirements for Registration of Pharmaceuticals\nfor Human Use, S2 (R1) 2011 https:\/\/database.ich.org\/sites\/default\/files\/S2_R1_Guideline.pdf."},{"key":"ref12\/cit12","unstructured":"National Pharmacopoeia Commission. Guidelines for the Control of Genotoxic\nImpurities\n(First draft) 2019 https:\/\/www.chp.org.cn\/ydw\/upload\/userfiles\/20190123\/641548209919095.pdf."},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.021"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.04.021"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.0c00323"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1002\/ejoc.202100363"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1002\/9781119551249.ch10"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.04.016"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.12.022"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.0c00224"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02120"},{"key":"ref22\/cit22","unstructured":"FDA 2021. Pfizer expands\nvoluntary nationwide recall to include all lots of CHANTIX (Varenicline)\ntablets due to N-nitroso varenicline content 2023 https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/pfizer-expands-voluntary-nationwide-recall-include-all-lots-chantixr-varenicline-tablets-due-n (accessed May 13)."},{"key":"ref23\/cit23","unstructured":"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/lupin-pharmaceuticals-inc-issues-voluntarily-nationwide-recall-all-irbesartan-tablets-and-irbesartan."},{"key":"ref24\/cit24","unstructured":"FDA 2022. Pfizer voluntary\nnationwide recall of lots of ACCUPRIL (Quinapril HCl) due to N-nitroso-quinapril\ncontent 2022 https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/pfizer-voluntary-nationwide-recall-lots-accuprilr-quinapril-hcl-due-n-nitroso-quinapril-content (accessed May 23)."},{"key":"ref25\/cit25","unstructured":"FDA 2022. Sandoz,\nInc. Issues nationwide recall of 13 lots of orphenadrine citrate 100\nmg extended-release tablets due to presence of a nitrosamine impurity 2023 https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/sandoz-inc-issuesnationwide-recall-13-lots-orphenadrine-citrate-100-mg-extended-release-tablets-due (accessed May 13)."},{"key":"ref26\/cit26","unstructured":"Health Canada\n2022. Pfizer recalls Inderal-LA\n(propranolol hydrochloride) capsules due\nto a nitrosamine impurity 2023 https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/pfizer-recalls-inderal-propranolol-hydrochloride-capsules-due-nitrosamine-impurity (accessed May 13)."},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.016"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01498"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.1c00369"},{"key":"ref30\/cit30","unstructured":"Guidance\nfor Industry U.S. Department of Health and Human Services Food and\nDrug Administration. Recommended\nAcceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities\n(NDSRIs), Center for Drug Evaluation and Research\n(CDER), Pharmacology\/Toxicology (accessed August 30, 2023)."},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.11.013"},{"key":"ref32\/cit32","unstructured":"ICH M7(R1). Assessment\nand control of DNA reactive (mutagenic) impurities in pharmaceuticals\nto limit potential carcinogenic risk, Current Step\n4 version dated 31 March, 2017 https:\/\/database.ich.org\/sites\/default\/files\/M7_R1_Guideline.pdf."},{"key":"ref33\/cit33","unstructured":"2023 https:\/\/www.fda.gov\/drugs\/mitigation-strategies-nitrosamine-drug-substance-related-impurities-quality-and-bioequivalence (accessed May 13)."},{"key":"ref34\/cit34","unstructured":"2023 https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impuritiesaccessed May 13."},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa962"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.9b00238"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lwt.2021.113008"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1007\/s13197-013-1133-5"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.111.959528"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","unstructured":"Ashworth, I. W.; Blanazs, A.; Byrne, J. J.; Dirat, O.; Fennel, J. W.; Kuhl, N.; Wells, S. L.; Whiting, M. P. Approaches and Considerations for the Investigation and Synthesis of N-Nitrosamine Drug Substance-Related Impurities (NDSRIs) Org. Process. Res. Dev. 2023 10.1021\/acs.oprd.3c00084.","DOI":"10.1021\/acs.oprd.3c00084"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.1016\/0300-483x(95)03190-q"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100186"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104875"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01498"},{"key":"ref45\/cit45","unstructured":"2023 https:\/\/www.drugs.com\/dosage\/cipro.html (accessed May 13)."},{"key":"ref46\/cit46","unstructured":"United states Pharmacopeial Convention, Rockville,\nMaryland,\nUSA. USP General Chapter Chromatography,\nUSP-43-NF38, 6853. https:\/\/doi.org.10.31003\/uspnf_M99380_07_01."},{"key":"ref47\/cit47","unstructured":"ICH Q2(2) International Conference on Harmonization\nof Technical\nRequirements for Registration of Pharmaceuticals for Human Use, Topic\nQ2(R2): validation of analytical procedures: Text and methodology,\n(2005) 2023 https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1_Guideline.pdf (accessed May 13)."},{"key":"ref48\/cit48","unstructured":"United states\nPharmacopeial Convention, Rockville, Maryland,\nUSA. USP General Chapter Validation\nof compendial procedures, USP-43-NF38, 8166 2023 https:\/\/doi.org.10.31003\/uspnf_M99945_04_01 (accessed May 13)."},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22998-0"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1016\/j.talo.2023.100221"}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.3c05170","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.3c05170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:09:31Z","timestamp":1709032171000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acsomega.3c05170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,2,27]]}},"alternative-id":["10.1021\/acsomega.3c05170"],"URL":"https:\/\/doi.org\/10.1021\/acsomega.3c05170","relation":{},"ISSN":["2470-1343","2470-1343"],"issn-type":[{"value":"2470-1343","type":"print"},{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}